189 Preclinical activity of the poly (ADP-ribose) polymerase (PARP) inhibitor ABT-888 in combination with irinotecan in ovarian and triple negative breast cancers

N. Nechiporchik; K. Lieb; L. Marquette; L. Polin; G.J. Peters; A. Chen; S.P. Ethier; P.M. LoRusso; A.M. Burger

首页> 外文期刊>European Journal of Cancer Supplements >189 Preclinical activity of the poly (ADP-ribose) polymerase (PARP) inhibitor ABT-888 in combination with irinotecan in ovarian and triple negative breast cancers

【24h】

189 Preclinical activity of the poly (ADP-ribose) polymerase (PARP) inhibitor ABT-888 in combination with irinotecan in ovarian and triple negative breast cancers

机译：189聚（ADP-核糖）聚合酶（PARP）抑制剂ABT-888与伊立替康联合在卵巢癌和三阴性乳腺癌中的临床前活性

获取原文

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

团队文献服务 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European Journal of Cancer Supplements 》 |2010年第7期| 共页
作者
N. Nechiporchik; K. Lieb; L. Marquette; L. Polin; G.J. Peters; A. Chen; S.P. Ethier; P.M. LoRusso; A.M. Burger;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学 ;
关键词

相似文献

外文文献
中文文献
专利

1. Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors [J] . LoRusso Patricia M., Li Jing, Burger Angelika, Clinical cancer research: an official journal of the American Association for Cancer Research . 2016 ,第13期

机译：晚期实体瘤患者中聚（ADP-核糖）聚合酶（PARP）抑制剂维利巴利（ABT-888）与依立替康联用的I期安全性，药代动力学和药效学研究
2. G2 Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): results of a randomized phase II trial [J] . J.OShaughnessy, C.Osborne, J.Pippen, European Journal of Cancer Supplements . 2009 ,第3期

机译：聚（ADP-核糖）聚合酶-1（PARP1）抑制剂BSI-201与吉西他滨/卡铂（G / C）联用在转移性三阴性乳腺癌（TNBC）患者中的G2疗效：随机结果II期试验
3. Differential anti-proliferative activities of poly(ADP-ribose) polymerase (PARP) inhibitors in triple-negative breast cancer cells. [J] . Hsiao-Ching Chuang, Naval Kapuriya, Samuel K Kulp, Breast cancer research and treatment. . 2012 ,第2期

机译：聚（ADP-核糖）聚合酶（PARP）抑制剂在三阴性乳腺癌细胞中的差异性抗增殖活性。
4. DESIGN AND SYNTHESIS OF NOVEL POLY ADP-RIBOSE POLYMERASE 1(PARP1)INHIBITORS FOR THE TREATMENT OF SOLID TUMORS [C] . J.Priyancy, D.P.Bhumika Conference on Drug Design and Discovery Technologies . 2020

机译：用于治疗实体肿瘤的新型聚ADP-核糖聚合酶1（PARP1）抑制剂的设计与合成
5. Molecular determinants of sensitivity to poly(ADP-ribose) polymerase inhibitors in epithelial ovarian cancer. [D] . O'Connor, Kevin. 2016

机译：分子决定因素对上皮性卵巢癌中聚（ADP-核糖）聚合酶抑制剂的敏感性。
6. Phase I safety pharmacokinetic and pharmacodynamic study of the poly (ADP-ribose) polymerase (PARP) inhibitor veliparib (ABT-888) in combination with irinotecan in patients with advanced solid tumors [O] . Patricia M. LoRusso, Jing Li, Angelika Burger, -1

机译：聚（ADP-核糖）聚合酶（PARP）抑制剂veliparib（ABT-888）与伊立替康联合治疗晚期实体瘤的I期安全性药代动力学和药效学研究
7. A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer [O] . Joyce F. Liu, Sara M. Tolaney, Michael Birrer, 2013

机译：聚（ADP-核糖）聚合酶抑制剂OLAPARIB（AZD2281）的相1试验与抗血管生成的Cediranib（AZD2171）组合在复发上皮卵巢癌或三阴性乳腺癌中
8. Treatment of BRCA1/2 Hereditary Breast Cancer and Sporadic Breast Cancer with Poly(ADP-ribose) PARP-1 Inhibitors and Chemotherapy [R] . DeSoto, J. A. 2008

机译：聚（aDp-核糖）paRp-1抑制剂和化疗治疗BRCa1 / 2遗传性乳腺癌和散发性乳腺癌

189 Preclinical activity of the poly (ADP-ribose) polymerase (PARP) inhibitor ABT-888 in combination with irinotecan in ovarian and triple negative breast cancers

著录项

相似文献

相关主题

期刊订阅